{"id":"angiomax-bivalirudin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dyspnea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bivalirudin is a synthetic peptide that directly inhibits thrombin (Factor IIa), a key enzyme in the coagulation cascade responsible for converting fibrinogen to fibrin and activating platelets. Unlike heparin, which requires antithrombin III as a cofactor, bivalirudin binds directly to both the active site and exosite I of thrombin, providing rapid and predictable anticoagulation. It is used during percutaneous coronary intervention to prevent thrombotic complications.","oneSentence":"Bivalirudin is a direct thrombin inhibitor that binds to and blocks thrombin, preventing blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:45.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anticoagulation during percutaneous coronary intervention (PCI)"},{"name":"Acute coronary syndrome (ACS) in patients undergoing PCI"}]},"trialDetails":[{"nctId":"NCT07383155","phase":"PHASE4","title":"Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-02-01","conditions":"Percutaneous Coronary Intervention, High Bleeding Risk, Acute Coronary Syndromes","enrollment":5270},{"nctId":"NCT06080074","phase":"PHASE2","title":"Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-04-15","conditions":"Heart Failure, Cardiogenic Shock, Congenital Heart Disease","enrollment":50},{"nctId":"NCT03537586","phase":"NA","title":"A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2018-06-29","conditions":"Coronary Microvascular Disease, Ischemic Heart Disease, Myocardial Ischemia","enrollment":206},{"nctId":"NCT06275555","phase":"NA","title":"Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation","status":"RECRUITING","sponsor":"Xiaotong Hou","startDate":"2024-06-03","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":154},{"nctId":"NCT03822975","phase":"NA","title":"Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2019-02-14","conditions":"ST Elevation Myocardial Infarction","enrollment":6016},{"nctId":"NCT05984537","phase":"PHASE4","title":"A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2023-07-01","conditions":"Coronary Microvascular Dysfunction","enrollment":70},{"nctId":"NCT03532399","phase":"","title":"Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2018-07-12","conditions":"Drug Effect","enrollment":30},{"nctId":"NCT06861374","phase":"NA","title":"Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-05","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":2400},{"nctId":"NCT05959252","phase":"PHASE2","title":"BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation","status":"RECRUITING","sponsor":"Sydney Local Health District","startDate":"2024-05-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":80},{"nctId":"NCT03664180","phase":"PHASE4","title":"Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-01-11","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":2989},{"nctId":"NCT03318393","phase":"PHASE4","title":"Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-03-25","conditions":"Extracorporeal Membrane Oxygenation Complication, Pediatric ALL, Anticoagulants","enrollment":30},{"nctId":"NCT05334654","phase":"NA","title":"Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"2022-04-20","conditions":"Acute Respiratory Failure, SARS CoV 2 Infection, Anticoagulants","enrollment":58},{"nctId":"NCT04120961","phase":"NA","title":"Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study)","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2019-09-20","conditions":"Coronary Heart Disease","enrollment":330},{"nctId":"NCT04475835","phase":"NA","title":"Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMI","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-01-12","conditions":"STEMI With Multivessel Coronary Disease","enrollment":100},{"nctId":"NCT03588611","phase":"PHASE4","title":"Reduce Bolus Injection of Bivalirudin","status":"COMPLETED","sponsor":"Han Yaling, MD","startDate":"2019-10-01","conditions":"Acute Coronary Syndrome","enrollment":204},{"nctId":"NCT01270139","phase":"NA","title":"Plasmonic Nanophotothermal Therapy of Atherosclerosis","status":"COMPLETED","sponsor":"Ural State Medical University","startDate":"2007-04-01","conditions":"Stable Angina, Heart Failure, Atherosclerosis","enrollment":180},{"nctId":"NCT03707418","phase":"PHASE1","title":"Bivalirudin vs Heparin in ECMO Patients","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2021-04","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":""},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT00812383","phase":"PHASE2","title":"Carotid With Bivalirudin Angioplasty","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2003-08","conditions":"Carotid Artery Disease","enrollment":299},{"nctId":"NCT00759083","phase":"PHASE4","title":"Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients","status":"WITHDRAWN","sponsor":"The Medicines Company","startDate":"2008-09","conditions":"Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome","enrollment":""},{"nctId":"NCT04532333","phase":"PHASE3","title":"Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2020-08","conditions":"Subarachnoid Hemorrhage, Aneurysmal","enrollment":236},{"nctId":"NCT04445935","phase":"PHASE4","title":"Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2020-06-28","conditions":"Anticoagulation in COVID-19 ARDS","enrollment":100},{"nctId":"NCT04195997","phase":"PHASE4","title":"Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-02-01","conditions":"Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk","enrollment":100},{"nctId":"NCT04185077","phase":"PHASE4","title":"Bivalirudin in Late PCI for Oatients With STEMI","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2019-11-30","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":1200},{"nctId":"NCT04046029","phase":"PHASE4","title":"Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2019-07-08","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention, Aging","enrollment":240},{"nctId":"NCT03965208","phase":"PHASE4","title":"Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation","status":"UNKNOWN","sponsor":"Legacy Health System","startDate":"2019-05-23","conditions":"Extracorporeal Membrane Oxygenation Complication, Anticoagulants","enrollment":34},{"nctId":"NCT00669149","phase":"PHASE4","title":"Anticoagulant Treatments and Percutaneous Coronary Angioplasty","status":"TERMINATED","sponsor":"Centre Hospitalier de PAU","startDate":"2008-06","conditions":"Coronary Artery Disease","enrollment":99},{"nctId":"NCT03882775","phase":"PHASE4","title":"Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2019-01-16","conditions":"STEMI, Percutaneous Coronary Intervention, Aged","enrollment":240},{"nctId":"NCT00073580","phase":"PHASE3","title":"Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2003-10","conditions":"Thrombocytopenia, Thrombosis, Cardiac Disease","enrollment":88},{"nctId":"NCT02565147","phase":"PHASE3","title":"Bivalirudin Infusion for Ventricular Infarction Limitation","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2014-12-19","conditions":"Acute Myocardial Infarction","enrollment":78},{"nctId":"NCT03567408","phase":"PHASE2","title":"Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)","status":"UNKNOWN","sponsor":"Qian Gong","startDate":"2018-09-15","conditions":"Coronary Heart Disease","enrollment":200},{"nctId":"NCT03182855","phase":"PHASE4","title":"Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2018-09-01","conditions":"Acute Coronary Syndrome, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction","enrollment":80},{"nctId":"NCT02448550","phase":"PHASE3","title":"Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial","status":"TERMINATED","sponsor":"Kaiser Permanente","startDate":"2015-05","conditions":"Percutaneous Coronary Intervention","enrollment":250},{"nctId":"NCT01245725","phase":"PHASE3","title":"Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention","status":"WITHDRAWN","sponsor":"Medicure","startDate":"","conditions":"Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina","enrollment":""},{"nctId":"NCT01084993","phase":"PHASE4","title":"EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding","status":"UNKNOWN","sponsor":"Laval University","startDate":"2010-03","conditions":"Coronary Artery Disease","enrollment":2000},{"nctId":"NCT00433966","phase":"PHASE3","title":"Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Cardiovascular Research Foundation, New York","startDate":"2005-03","conditions":"Myocardial Infarction","enrollment":3602},{"nctId":"NCT01913483","phase":"PHASE3","title":"ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2013-09-24","conditions":"Peripheral Endovascular Interventions, Bleeding","enrollment":732},{"nctId":"NCT02311231","phase":"PHASE4","title":"Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2014-06","conditions":"ST-segment Elevation Myocardial Infarction, Non ST-segment Elevation Myocardial Infarction","enrollment":6012},{"nctId":"NCT01651780","phase":"PHASE3","title":"Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2012-10","conditions":"Severe Aortic Stenosis, Transcatheter Aortic Valve Replacement, Aortic Valve Replacement","enrollment":803},{"nctId":"NCT01789814","phase":"PHASE4","title":"Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2013-07","conditions":"Coronary Artery Disease","enrollment":24},{"nctId":"NCT02384070","phase":"NA","title":"Simplified Anti-Thrombotic Therapy for FFR","status":"COMPLETED","sponsor":"Odessa Heart Institute","startDate":"2009-01","conditions":"Coronary Artery Disease","enrollment":300},{"nctId":"NCT02897037","phase":"PHASE3","title":"Bivalirudin in Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2016-11","conditions":"Acute Myocardial Infarction","enrollment":380},{"nctId":"NCT00812370","phase":"PHASE1","title":"The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2008-09","conditions":"Deep Venous Thrombosis","enrollment":18},{"nctId":"NCT01642238","phase":"PHASE4","title":"Antithrombotic Effects of Ticagrelor Versus Clopidogrel","status":"COMPLETED","sponsor":"Juan J Badimon","startDate":"2012-07","conditions":"Acute Coronary Syndrome","enrollment":15},{"nctId":"NCT02787317","phase":"PHASE4","title":"Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-05","conditions":"Coronary Disease","enrollment":1770},{"nctId":"NCT02052635","phase":"PHASE4","title":"Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Non-ST Elevation Acute Coronary Syndrome","enrollment":34},{"nctId":"NCT01848899","phase":"PHASE4","title":"Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2013-02","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT02592720","phase":"PHASE4","title":"Cocktail Injection Improves Outcomes of FFR Guided PCI","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2015-10","conditions":"Acute Coronary Syndromes","enrollment":500},{"nctId":"NCT02592694","phase":"PHASE4","title":"Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2015-10","conditions":"ST-elevation Myocardial Infarction","enrollment":1000},{"nctId":"NCT01747174","phase":"PHASE2","title":"REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction","status":"COMPLETED","sponsor":"University Hospitals, Leicester","startDate":"2011-10","conditions":"ST-elevation Myocardial Infarction (STEMI)","enrollment":247},{"nctId":"NCT00616460","phase":"PHASE3","title":"ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2008-02","conditions":"Hematologic Diseases","enrollment":100},{"nctId":"NCT01519518","phase":"PHASE4","title":"How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2012-02","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":1829},{"nctId":"NCT01433627","phase":"PHASE3","title":"Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2011-10","conditions":"Acute Coronary Syndromes, STEMI, NSTEMI","enrollment":7200},{"nctId":"NCT01464671","phase":"PHASE4","title":"Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention","status":"TERMINATED","sponsor":"Stony Brook University","startDate":"2009-07","conditions":"Coronary Artery Disease","enrollment":260},{"nctId":"NCT01848106","phase":"PHASE3","title":"A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI","status":"TERMINATED","sponsor":"Regado Biosciences, Inc.","startDate":"2013-09","conditions":"Coronary Artery Disease","enrollment":3232},{"nctId":"NCT02268669","phase":"PHASE4","title":"Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI","status":"UNKNOWN","sponsor":"GRACIA Group","startDate":"2010-05","conditions":"Myocardial Infarction","enrollment":1444},{"nctId":"NCT01696110","phase":"PHASE4","title":"BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2012-08","conditions":"Acute Myocardial Infarction, Percutaneous Coronary Intervention","enrollment":2194},{"nctId":"NCT01510171","phase":"PHASE4","title":"Rapid Activity of Platelet Inhibitor Drugs Study","status":"COMPLETED","sponsor":"Careggi Hospital","startDate":"2012-01","conditions":"ST-segment Elevation Myocardial Infarction","enrollment":50},{"nctId":"NCT01805570","phase":"PHASE4","title":"Rapid Activity of Platelet Inhibitor Drugs Study 2","status":"COMPLETED","sponsor":"David Antoniucci","startDate":"2012-11","conditions":"Myocardial Infarction","enrollment":50},{"nctId":"NCT01273350","phase":"NA","title":"A Prospective, Non-Randomized, Evaluation of Low-Risk Patients Undergoing Carotid Stenting With ANgiomax (Bivalirudin)","status":"UNKNOWN","sponsor":"SPSI d.b.a Capital Cardiovascular Associates","startDate":"2004-10","conditions":"Carotid Stenosis","enrollment":154},{"nctId":"NCT01465503","phase":"PHASE3","title":"Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients","status":"COMPLETED","sponsor":"Clinica Mediterranea","startDate":"2008-01","conditions":"Bleeding","enrollment":837},{"nctId":"NCT00976092","phase":"PHASE4","title":"Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2009-09","conditions":"Myocardial Infarction","enrollment":548},{"nctId":"NCT01971788","phase":"NA","title":"The MATRIX OCT Substudy","status":"UNKNOWN","sponsor":"S.M. Misericordia Hospital","startDate":"2013-06","conditions":"Acute Myocardial Infarction, Coronary Stent Thrombosis, Antithrombotic Therapy","enrollment":160},{"nctId":"NCT00464087","phase":"PHASE3","title":"Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2007-06","conditions":"Acute Coronary Syndromes","enrollment":100},{"nctId":"NCT00842374","phase":"","title":"Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin","status":"COMPLETED","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2008-12","conditions":"Non-STEMI Acute Coronary Syndrome","enrollment":32},{"nctId":"NCT01647893","phase":"PHASE1","title":"Phase 1 Single Dose Escalation Study of CTB-001","status":"UNKNOWN","sponsor":"HLB Pharmaceutical Co., Ltd.","startDate":"2012-07","conditions":"Healthy","enrollment":33},{"nctId":"NCT00373451","phase":"PHASE4","title":"Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2006-07","conditions":"Myocardial Infarction, Coronary Disease","enrollment":1721},{"nctId":"NCT00317343","phase":"","title":"RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)","status":"WITHDRAWN","sponsor":"Nycomed","startDate":"2006-03","conditions":"Coronary Disease","enrollment":""},{"nctId":"NCT00290849","phase":"","title":"ImproveR International (BI-001-IM)","status":"COMPLETED","sponsor":"Nycomed","startDate":"2005-03","conditions":"Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)","enrollment":4000},{"nctId":"NCT00419055","phase":"","title":"Outpatient Percutaneous Coronary Intervention","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2004-08","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT01555658","phase":"PHASE3","title":"Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2012-04","conditions":"Coronary Artery Disease","enrollment":204},{"nctId":"NCT01011504","phase":"","title":"Utilisation of Angiox® in European Practice","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2009-05","conditions":"Stable Angina (SA), NSTE-ACS (NSTEMI and UA), STEMI (STE-ACS)","enrollment":2019},{"nctId":"NCT00079586","phase":"PHASE3","title":"Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2004-04","conditions":"Cardiovascular Disease, Coronary Artery Bypass Surgery","enrollment":150},{"nctId":"NCT00079508","phase":"PHASE3","title":"Angiomax in Patients With HIT/HITTS Type II Undergoing CPB","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2004-04","conditions":"Cardiovascular Disease, Coronary Artery Bypass Surgery","enrollment":125},{"nctId":"NCT00503126","phase":"PHASE2","title":"Bivalirudin as a Procedural Anticoagulant in Pediatrics","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2007-08","conditions":"Cardiology","enrollment":110},{"nctId":"NCT00073593","phase":"PHASE3","title":"Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2003-08","conditions":"Cardiac Surgery, Coronary Artery Bypass Surgery","enrollment":150},{"nctId":"NCT00043940","phase":"PHASE3","title":"Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"1999-04","conditions":"Heparin-Induced Thrombocytopenia, Thrombosis","enrollment":50},{"nctId":"NCT00398463","phase":"PHASE4","title":"Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2006-05","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":263},{"nctId":"NCT01274728","phase":"","title":"PAclitaxel-eluting Balloon in Primary PCI in Amsterdam; Pilot Study","status":"UNKNOWN","sponsor":"Onze Lieve Vrouwe Gasthuis","startDate":"2010-11","conditions":"Acute Myocardial Infarction","enrollment":100},{"nctId":"NCT01160900","phase":"PHASE3","title":"FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Camillo Forlanini","startDate":"2010-07","conditions":"Myocardial Infarction, Ischemia, Heart Failure","enrollment":180},{"nctId":"NCT01157455","phase":"PHASE4","title":"A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization","status":"UNKNOWN","sponsor":"CCRF Consulting Co., Ltd.","startDate":"2010-05","conditions":"Coronary Artery Diseases","enrollment":1900},{"nctId":"NCT01158846","phase":"PHASE4","title":"Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI","status":"UNKNOWN","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2010-08","conditions":"ST-Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention","enrollment":800},{"nctId":"NCT00262054","phase":"PHASE4","title":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2005-11","conditions":"Coronary Disease, Angina Pectoris","enrollment":4570},{"nctId":"NCT00448461","phase":"PHASE4","title":"Antithrombotic Regimens and Outcome","status":"COMPLETED","sponsor":"Careggi Hospital","startDate":"2007-03","conditions":"Coronary Artery Disease","enrollment":850},{"nctId":"NCT00391326","phase":"","title":"Efficacy and Safety of Prehospital Administration of Bivalirudin in STEMI Patients","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2006-11","conditions":"Acute Myocardial Infarction","enrollment":102},{"nctId":"NCT00093158","phase":"PHASE3","title":"Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2003-08","conditions":"Unstable Angina, Myocardial Infarction, Acute Disease","enrollment":13800},{"nctId":"NCT00476944","phase":"PHASE4","title":"Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI","status":"UNKNOWN","sponsor":"Gold, Herman K., MD","startDate":"2006-09","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT00370045","phase":"PHASE4","title":"Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin","status":"UNKNOWN","sponsor":"LifeBridge Health","startDate":"2006-03","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT00093184","phase":"PHASE3","title":"Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2004-04","conditions":"Myocardial Infarction","enrollment":300},{"nctId":"NCT00043277","phase":"PHASE2","title":"Study Of Angiomax In Infants Under Six Months With Thrombosis","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2002-08","conditions":"Thrombosis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"THROMBOSIS IN DEVICE"},{"count":3,"reaction":"MYOCARDIAL INFARCTION"},{"count":2,"reaction":"ACUTE RESPIRATORY DISTRESS SYNDROME"},{"count":2,"reaction":"ATELECTASIS"},{"count":2,"reaction":"CORONARY ARTERY THROMBOSIS"},{"count":2,"reaction":"ELECTROCARDIOGRAM ST SEGMENT ELEVATION"},{"count":2,"reaction":"POST PROCEDURAL COMPLICATION"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"BLOOD POTASSIUM DECREASED"}],"_approvalHistory":[],"publicationCount":1882,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Angiomax (bivalirudin)","genericName":"Angiomax (bivalirudin)","companyName":"The Medicines Company","companyId":"the-medicines-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bivalirudin is a direct thrombin inhibitor that binds to and blocks thrombin, preventing blood clot formation. Used for Anticoagulation during percutaneous coronary intervention (PCI), Acute coronary syndrome (ACS) in patients undergoing PCI.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}